By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Peptimmune, Inc. 

64 Sidney Street
Suite 380
Cambridge  Massachusetts  02139-4136  U.S.A.
Phone: 617-715-8000 Fax: 617-661-8855




Medivir  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Novartis Corporation  Exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune’s multiple sclerosis drug candidate.

Company News
Merck Serono Buys Potential Copaxone Competitor from Bankrupt Peptimmune, Inc. 9/19/2011 8:20:03 AM
Peptimmune, Inc. Files Under Chapter 7 3/23/2011 8:16:06 AM
Peptimmune, Inc. Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone 10/4/2010 10:06:16 AM
Peptimmune, Inc. Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 8/25/2009 10:49:29 AM
Peptimmune, Inc. Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis; Payments Could Total More Than $500 Million 1/15/2009 8:20:08 AM
'Unprecedented' Biotech Bankruptcies Erupt Amid Finance Crisis 11/21/2008 12:59:34 PM
Peptimmune, Inc. Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis 9/17/2008 8:26:00 AM
Peptimmune, Inc. Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 7/31/2008 7:55:58 AM
Peptimmune, Inc. Announces the Second Close of Series D Private Financing 7/16/2008 11:13:45 AM
Peptimmune, Inc. Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients 6/17/2008 9:55:20 AM